Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours

Oberg, 2005, Endocrine tumours of the pancreas, Best Pract Res Clin Gastroenterol, 19, 753, 10.1016/j.bpg.2005.06.002 Goh, 2006, Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine, Neoplasm, 6, 520 Solcia, 2000 Panzuto, 2005, Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization, Endocr Relat Cancer, 12, 1083, 10.1677/erc.1.01017 Alexander, 2005, Pancreatic endocrine tumours, 2, 1540 Peracchi, 2003, Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumours or multiple endocrine neoplasia type 1, Eur J Endocrinol, 148, 39, 10.1530/eje.0.1480039 Taupenot, 2003, The chromogranin secretogranin family, N Engl J Med, 348, 1134, 10.1056/NEJMra021405 Dromain, 2005, Detection of liver metastases from endocrine tumours: a prospective comparison of somatostatin receptor scintigraphy, computed tomography and magnetic resonance imaging, J Clin Oncol, 23, 70, 10.1200/JCO.2005.01.013 Rodallec, 2006, Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival, Pancreatology, 6, 77, 10.1159/000090026 Oberg, 2005, Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours, Best Pract Res Clin Endocrinol Metabol, 19, 265, 10.1016/j.beem.2004.11.016 Nikou, 2005, Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues, Hepatogastroenterology, 52, 731 Nikou, 1995, Somatostatin-receptor imaging in the diagnosis and management of gut endocrine tumours, Hell J Gastroenterol, 8, 312 Zimmer, 1994, Endosonography of neuroendocrine tumours of the stomach, duodenum and pancreas, Ann NY Acad Sci, 733, 425, 10.1111/j.1749-6632.1994.tb17292.x Calender, 2000, Molecular genetics of neuroendocrine tumours, Digestion, 62, 3, 10.1159/000051850 Alexakis, 2004, Hereditary pancreatic endocrine tumours, Pancreatology, 4, 417, 10.1159/000079616 DeLellis, 2004 Odze, 2004 Wiedenmann, 1998, Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumours: general recommendations by a consensus workshop, World J Surg, 22, 309, 10.1007/s002689900387 Grazi, 2000, Highly aggressive policy of hepatic resections for neuroendocrine liver metastases, Hepatogastroenterology, 47, 481 Ducreux, 2000, The antitumoural effect of the long-acting somatostatin analogue lanreotide in neuroendocrine tumours, Am J Gastroenterol, 95, 3276, 10.1111/j.1572-0241.2000.03210.x Arnold, 1996, Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours, Gut, 38, 430, 10.1136/gut.38.3.430 Bodei, 2003, Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study, Eur J Nucl Med Mol Imaging, 30, 207, 10.1007/s00259-002-1023-y Kwekkeboom, 2005, Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumours, J Clin Oncol, 23, 2754, 10.1200/JCO.2005.08.066 O'Toole, 2004, Chemotherapy for gastro-enteropancreatic neuroendocrine tumours, Neuroendocrinology, 80, 79, 10.1159/000080747 Kulke, 2004, A phase II trial of gemcitabine for metastatic neuroendocrine tumours, Cancer, 101, 934, 10.1002/cncr.20466 Kulke, 2004, A phase II study of docetaxel in patients with metastatic neuroendocrine tumours, Cancer Invest, 22, 353, 10.1081/CNV-200029058 Rusniewski, 2000, Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours, Digestion, 62, 79, 10.1159/000051860 Berber, 2002, Laparoscopic radiofrequency ablation of neuroendocrine liver metastases, World J Surg, 26, 985, 10.1007/s00268-002-6629-5 Tomassetti, 2005, Endocrine pancreatic tumours: factors correlated with survival, Ann Oncol, 16, 1806, 10.1093/annonc/mdi358